Fact Sheet

About:

BIOCON is a fully-integrated, innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and taken differentiated Small Molecules, Novel Biologics and a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh-Insulin and Insulin Glargine) from 'Lab to Market' in India, key emerging and developed markets. It has a large portfolio of biosimilars under clinical development with three of these approved in developed markets of US, EU, Japan and Australia. Its Novel pipeline includes promising assets like Insulin Tregopil, anti-CD6 antibody and a fusion protein for immuno-oncology. Some of its key brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab).

A Credible Biopharma Enterprise:

- ~1,400 Patents Filed Globally
- ~1,150 Patents Granted
- ~690 Trademarks Registered
- 9 Biologics taken from 'Lab to Market': 2 Novels & 7 Biosimilars
- ~120 Countries where our Products are Available
- 25+ cGMP Approvals from International Regulatory Agencies*
- **Key Brands:** INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab), GCC etc.

Vision

To enhance global healthcare through innovative and affordable biopharma products for patients, partners and healthcare systems across the globe.

*As of 31 March 2018
Biocon at a Glance:

- First listed 'pure play' biopharmaceuticals company in India.
- First to launch an indigenously developed novel biologic in India.
- First company from India to have a biosimilar commercialized in the U.S.
- First company from India to have a biosimilar commercialized in Japan.
- First novel anti-CD6 monoclonal antibody developed and launched anywhere in the world by Biocon.
- Largest statins producer; Biocon's drug substances are used to produce '1 in every 3' statin pills globally.

- Largest biologics manufacturing capacity in India.
- Largest insulins manufacturing complex in Asia set up by Biocon in Malaysia.
- Largest integrated biotech hub, 90-acre Biocon Park, located in Bangalore.
- Among Top 3 biosimilar players globally for rh-Insulin & Insulin Glargine in terms of volume market share.
- Wide presence with marketing footprint across 120 countries.
Growth Verticals: Aligned with Shifting Paradigms

**BIOLOGICS**
**Novel Biologics & Biosimilars**
(rh-insulin, Insulin Analogs, Monoclonal Antibodies & Recombinant Proteins)

**BRANDED FORMULATIONS**
Finished Dosage Business in India & Overseas

**SMALL MOLECULES**
Differentiated APIs & Generic Formulations

**RESEARCH SERVICES**
**Syngene**
(Molecular Biology, Biologics, Synthetic Chemistry, Bioinformatics & Clinical Research)

---

For more information contact:

**Seema Ahuja**
VP & Global Head of Communications
T: +91-80-2808-2222
Email: seema.ahuja@biocon.com

Issued by Corporate Communications | Email: corporate.communications@biocon.com | www.biocon.com